Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Ambry Genetics Corp.
DescriptionNext-generation sequencing (NGS) panel that analyzes 23 genes associated with increased risk for breast, ovarian and/or uterine cancers
Molecular Target
Mechanism of Action 
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetect increased risk for breast, ovarian, and/or uterine cancers
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today